6:05 PM
Apr 23, 2013
 |  BC Extra  |  Top Story

AbbVie reports SVR24 data for all-oral regimen

AbbVie Inc. (NYSE:ABBV) reported additional data from the Phase IIb Aviator (Study M11-652) trial of an interferon-free regimen that includes three of Abbott's antivirals to treat HCV genotype 1 infection in non-cirrhotic patients. The regimen -- ABT-450 plus ritonavir, ABT-267, ABT-333 and ribavirin for 12 weeks -- produced a sustained virologic response (SVR) 24 weeks after the end of treatment in 96% of...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >